항기생충제 시장 규모, 점유율, 성장 분석 : 약물 계열별, 적응증별, 투여 경로별, 최종사용자별, 유통 채널별, 환자 유형별, 지역별 - 업계 예측(2026-2033년)

Global Antiparasitic Drugs Market size was valued at USD 14.87 Billion in 2024 and is poised to grow from USD 15.58 Billion in 2025 to USD 22.68 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).

The global antiparasitic drugs market is witnessing significant growth driven by the increasing health demands and agricultural production needs. This sector has transitioned from addressing basic treatments for malaria and helminth infections to addressing more complex challenges posed by tropical diseases and intensified livestock production. The rise in demand is largely attributed to advancements in treatment options, such as artemisinin-based combination therapies and innovative ivermectin formulations for veterinary use. Regulatory support aimed at controlling zoonotic diseases is a significant market driver, prompting manufacturers to develop safer, effective formulations for both humans and animals. As a result, investments in combination products, like dual-action anthelmintic-insecticides, have emerged, enhancing cost-effectiveness and expansion into emerging markets, solidifying the competitive landscape for multifunctional therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antiparasitic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antiparasitic Drugs Market Segments Analysis

Global antiparasitic drugs market is segmented by drug class, indication, route of administration, end user, distribution channel, patient type and region. Based on drug class, the market is segmented into anthelmintics, antiprotozoal drugs, ectoparasiticides and others. Based on indication, the market is segmented into helminthic infections, protozoal infections, ectoparasitic infections and others. Based on route of administration, the market is segmented into oral, injectable, topical and others. Based on end user, the market is segmented into hospitals, clinics, homecare and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. Based on patient type, the market is segmented into human healthcare and veterinary healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antiparasitic Drugs Market

The Global Antiparasitic Drugs market is driven by the growing prevalence of parasitic diseases among both humans and animals, prompting a heightened need for effective treatments. Factors such as climate change, urbanization, and increased travel are broadening the geographic distribution of disease vectors, introducing new patient populations to potential infections. In response, healthcare providers and veterinary practitioners are prioritizing both preventive and therapeutic measures, which encourages pharmaceutical companies to expand their product pipelines. This rising awareness promotes the use of combination therapies and stimulates research and development efforts, ultimately enhancing clinical usage and bolstering confidence in prescriptions. Additionally, regulatory bodies are facilitating faster approval processes for essential antiparasitic therapies.

Restraints in the Global Antiparasitic Drugs Market

The global antiparasitic drugs market faces significant constraints due to rigorous regulatory requirements that mandate comprehensive evaluations of safety, efficacy, and quality. This necessity for in-depth pre-clinical and clinical testing demands extensive documentation and repeated assessments, leading to heightened operational complexity. Such stringent scrutiny can result in delays in product launches, hindering manufacturers from swiftly addressing emerging parasitic challenges. Consequently, the burdensome compliance obligations can stifle innovation and research efforts among companies, contributing to a slowdown in overall market momentum. As a result, growth opportunities within this highly regulated sector may be significantly restricted.

Market Trends of the Global Antiparasitic Drugs Market

The Global Antiparasitic Drugs market is experiencing significant growth driven by increasing pet ownership and heightened awareness regarding animal health. This surge in demand for antiparasitic treatments, particularly within the veterinary segment, is prompting manufacturers to innovate with novel formulations and combination therapies that prioritize safety and efficacy for pets and livestock. Additionally, the rise of online pet pharmacies is enhancing distribution channels, making these products more accessible. This trend not only diversifies revenue streams beyond human medicine but also encourages investment in research aimed at targeting specific parasites and developing strategies for resistance management and long-term effectiveness.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Antiparasitic Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Anthelmintics
• Antiprotozoal Drugs
• Ectoparasiticides
• Others

Global Antiparasitic Drugs Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Helminthic Infections
• Protozoal Infections
• Ectoparasitic Infections
• Others

Global Antiparasitic Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical
• Others

Global Antiparasitic Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Homecare
• Others

Global Antiparasitic Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Antiparasitic Drugs Market Size by Patient Type & CAGR (2026-2033)

• Market Overview
• Human Healthcare
• Veterinary Healthcare

Global Antiparasitic Drugs Market Size & CAGR (2026-2033)

• North America (Drug Class, Indication, Route of Administration, End User, Distribution Channel, Patient Type)
  • US
  • Canada
• Europe (Drug Class, Indication, Route of Administration, End User, Distribution Channel, Patient Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Route of Administration, End User, Distribution Channel, Patient Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Route of Administration, End User, Distribution Channel, Patient Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Route of Administration, End User, Distribution Channel, Patient Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations